Home
Publications
Online Publications
Document
|
Policy for the Health Sector : Issues and options
Introducing effective, new, and affordable technologiesThe application of effective, new, and affordable technologies provides the DMCs with many opportunities to leapfrog problems that plagued rich countries during their development. Unfortunately in the past, these technological advances, especially in public health, were usually adopted very slowly. For example, measles vaccine was licensed in the early 1960s, yet it took almost 30 years before children in the region routinely benefited from this safe, inexpensive, and costeffective vaccine. This story looks ready to be repeated with two relatively new vaccines, hepatitis B and Hemophilus influenza B (Hib). Both are proven effective and are in widespread use in developed countries but have barely been introduced in the Bank’s DMCs. Hepatitis B vaccine, for example, prevents a disease that is widespread in the region, is low cost, and is easy to include in ongoing immunization activities but is available to less than 20 percent of the infants. With advances in biotechnology there will be many new technologies available in the next ten years that will be of huge benefit to the populations of the DMCs. Seizing the opportunities that these technologies provide will require political support and adequate financing. The Bank can play a leadership role by helping its DMCs make timely investments in deploying these technologies.
|